journal
MENU ▼
Read by QxMD icon Read
search

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring

journal
https://www.readbyqxmd.com/read/29780876/memory-concerns-in-the-early-alzheimer-s-disease-prodrome-regional-association-with-tau-deposition
#1
Cecily G Swinford, Shannon L Risacher, Arnaud Charil, Adam J Schwarz, Andrew J Saykin
Introduction: Relationship between self- and informant memory concerns and tau aggregation was assessed in adults at risk for Alzheimer's disease (AD). Methods: Regional mean standardized uptake value ratios were extracted from [18 F]flortaucipir positron emission tomography (PET) scans of 82 at-risk adults in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Associations between self- and informant ECog memory scores and tau aggregation were analyzed on both regional and voxelwise bases...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780875/amyloid-%C3%AE-peptides-are-differentially-vulnerable-to-preanalytical-surface-exposure-an-effect-incompletely-mitigated-by-the-use-of-ratios
#2
Jamie Toombs, Martha S Foiani, Henrietta Wellington, Ross W Paterson, Charles Arber, Amanda Heslegrave, Michael P Lunn, Jonathan M Schott, Selina Wray, Henrik Zetterberg
Introduction: We tested the hypothesis that the amyloid β (Aβ) peptide ratios are more stable than Aβ42 alone when biofluids are exposed to two preanalytical conditions known to modify measurable Aβ concentration. Methods: Human cerebrospinal fluid (CSF) and culture media (CM) from human cortical neurons were exposed to a series of volumes and polypropylene surfaces. Aβ42 , Aβ40 , and Aβ38 peptide concentrations were measured using a multiplexed electrochemiluminescence immunoassay...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780874/the-personalized-alzheimer-s-disease-cortical-thickness-index-predicts-likely-pathology-and-clinical-progression-in-mild-cognitive-impairment
#3
Annie M Racine, Michael Brickhouse, David A Wolk, Bradford C Dickerson
Introduction: An Alzheimer's disease (AD) biomarker adjusted for age-related brain changes should improve specificity for AD-related pathological burden. Methods: We calculated a brain-age-adjusted "personalized AD cortical thickness index" (pADi) in mild cognitive impairment patients from the Alzheimer's Disease Neuroimaging Initiative. We performed receiver operating characteristic analysis for discrimination between patients with and without cerebrospinal fluid evidence of AD and logistic regression in an independent sample to determine if a dichotomized pADi predicted conversion to AD dementia...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780873/advances-in-alzheimer-s-imaging-are-changing-the-experience-of-alzheimer-s-disease
#4
REVIEW
Shana D Stites, Richard Milne, Jason Karlawish
Neuroimaging is advancing a new definition of Alzheimer's disease (AD). Using imaging biomarkers, clinicians may begin to diagnose the disease by identifying pathology and neurodegeneration in either cognitively impaired or unimpaired adults. This "biomarker-based" diagnosis may allow clinicians novel opportunities to use interventions that either delay the onset or slow the progression of cognitive decline, but it will also bring novel challenges. How will changing the definition of AD from a clinical to a biomarker construct change the experience of living with the disease? Knowledge of AD biomarker status can affect how individuals feel about themselves (internalized stigma) and how others judge them (public stigma)...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780872/neuropsychology-and-neuroimaging-profiles-of-amyloid-positive-versus-amyloid-negative-amnestic-mild-cognitive-impairment-patients
#5
Clémence Tomadesso, Vincent de La Sayette, Robin de Flores, Pierrick Bourgeat, Victor L Villemagne, Stéphanie Egret, Francis Eustache, Gaël Chételat
Introduction: Patients with amnestic mild cognitive impairment (aMCI) are heterogeneous as regard to their amyloid status. The present study aimed at highlighting the neuropsychological, brain atrophy, and hypometabolism profiles of amyloid-positive (Aβpos) versus amyloid-negative (Aβneg) aMCI patients. Methods: Forty-four aMCI patients and 24 Aβneg healthy controls underwent neuropsychological, structural magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography scans...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780871/computer-based-evaluation-of-alzheimer-s-disease-and-mild-cognitive-impairment-patients-during-a-picture-description-task
#6
Laura Hernández-Domínguez, Sylvie Ratté, Gerardo Sierra-Martínez, Andrés Roche-Bergua
Introduction: We present a methodology to automatically evaluate the performance of patients during picture description tasks. Methods: Transcriptions and audio recordings of the Cookie Theft picture description task were used. With 25 healthy elderly control (HC) samples and an information coverage measure, we automatically generated a population-specific referent. We then assessed 517 transcriptions (257 Alzheimer's disease [AD], 217 HC, and 43 mild cognitively impaired samples) according to their informativeness and pertinence against this referent...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780870/similar-pattern-of-atrophy-in-early-and-late-onset-alzheimer-s-disease
#7
Carl Eckerström, Niklas Klasson, Erik Olsson, Per Selnes, Sindre Rolstad, Anders Wallin
Introduction: Previous research on structural changes in early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD) have reported inconsistent findings. Methods: In the present substudy of the Gothenburg MCI study, 1.5 T scans were used to estimate lobar and hippocampal volumes using FreeSurfer. Study participants (N = 145) included 63 patients with AD, (24 patients with EOAD [aged ≤65 years], 39 patients with LOAD [aged >65 years]), 25 healthy controls aged ≤65 years, and 57 healthy controls aged >65 years...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780869/cross-sectional-and-longitudinal-atrophy-is-preferentially-associated-with-tau-rather-than-amyloid-%C3%AE-positron-emission-tomography-pathology
#8
Brian A Gordon, Austin McCullough, Shruti Mishra, Tyler M Blazey, Yi Su, John Christensen, Aylin Dincer, Kelley Jackson, Russ C Hornbeck, John C Morris, Beau M Ances, Tammie L S Benzinger
Introduction: Structural magnetic resonance imaging is a marker of gray matter health and decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work has shown that both amyloid β (Aβ) and tau biomarkers are related to cortical thinning, but it is unclear what unique influences they have on the brain. Methods: Aβ pathology was measured with [18 F] AV-45 (florbetapir) positron emission tomography (PET) and tau was assessed with [18 F] AV-1451 (flortaucipir) PET in a population of 178 older adults, of which 123 had longitudinal magnetic resonance imaging assessments (average of 5...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780868/tau-positron-emission-tomography-imaging-in-tauopathies-the-added-hurdle-of-off-target-binding
#9
Laetitia Lemoine, Antoine Leuzy, Konstantinos Chiotis, Elena Rodriguez-Vieitez, Agneta Nordberg
Ligands targeting tau for use with positron emission tomography have rapidly been developed during the past several years, enabling the in vivo study of tau pathology in patients with Alzheimer's disease and related non-Alzheimer's disease tauopathies. Several candidate compounds have been developed, showing good in vitro characteristics with respect to their ability to bind tau deposits; off-target binding, however, has also been observed. In this short commentary, we briefly summarize the available in vivo and in vitro evidence pertaining to their off-target binding and discuss the different approaches that are needed for the future development of tau positron emission tomography tracers...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780867/topographic-staging-of-tau-positron-emission-tomography-images
#10
Adam J Schwarz, Sergey Shcherbinin, Lawrence J Slieker, Shannon L Risacher, Arnaud Charil, Michael C Irizarry, Adam S Fleisher, Sudeepti Southekal, Abhinay D Joshi, Michael D Devous, Bradley B Miller, Andrew J Saykin
Introduction: It has been proposed that the signal distribution on tau positron emission tomography (PET) images could be used to define pathologic stages similar to those seen in neuropathology. Methods: Three topographic staging schemes for tau PET, two sampling the temporal and occipital subregions only and one sampling cortical gray matter across the major brain lobes, were evaluated on flortaucipir F 18 PET images in a test-retest scenario and from Alzheimer's Disease Neuroimaging Initiative 2...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780866/molecular-imaging-what-is-right-and-what-is-an-illusion
#11
William E Klunk
Over the past 40 years, brain molecular imaging has evolved from measuring cerebral metabolism with fluorodeoxyglucose, to neuroreceptor imaging, to imaging pathological protein deposits. In the early going, the characteristics of successful molecular imaging radiotracers were defined, and a detailed "Process" was developed for the collection of basic pharmacodynamic and pharmacokinetic data. These data are essential for the interpretation of in vivo imaging data and for defining the strengths, weaknesses, and limitations of new tracers...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780865/elevated-medial-temporal-lobe-and-pervasive-brain-tau-pet-signal-in-normal-participants
#12
Val J Lowe, Tyler J Bruinsma, Hoon-Ki Min, Emily S Lundt, Ping Fang, Matthew L Senjem, Bradley F Boeve, Keith A Josephs, Mukesh K Pandey, Melissa E Murray, Kejal Kantarci, David T Jones, Christopher G Schwarz, David S Knopman, Ronald C Petersen, Clifford R Jack
Introduction: Medial temporal lobe (MTL) uptake on tau-positron emission tomography (PET) is seen not only in Alzheimer's disease (AD) dementia but also in the aging population. The relationship of these findings to the development of AD dementia needs to be better understood. Methods: Tau-PET with AV-1451 was performed on 576 cognitively unimpaired (CU) participants aged 50-94 years. The number of CUs with and without abnormal MTL regions and those with or without extra-MTL abnormalities was determined...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780864/change-in-retinal-structural-anatomy-during-the-preclinical-stage-of-alzheimer-s-disease
#13
Cláudia Y Santos, Lenworth N Johnson, Stuart E Sinoff, Elena K Festa, William C Heindel, Peter J Snyder
Introduction: We conducted a 27-month longitudinal study of mid-life adults with preclinical Alzheimer's disease (AD), using spectral domain optical coherence tomography to compare changes in volume and thickness in all retinal neuronal layers to those of age-matched healthy control subjects. Methods: Fifty-six older adults (mean age = 65.36 years) with multiple risk factors for AD completed spectral domain optical coherence tomography retinal imaging and cognitive testing at baseline...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780863/a-novel-cognitive-functional-composite-measure-to-detect-changes-in-early-alzheimer-s-disease-test-retest-reliability-and-feasibility
#14
Roos J Jutten, John Harrison, Philippe R Lee Meeuw Kjoe, Esther M Opmeer, Niki S M Schoonenboom, Frank Jan de Jong, Craig W Ritchie, Philip Scheltens, Sietske A M Sikkes
Introduction: To improve the detection of changes in Alzheimer's disease (AD), we designed the cognitive-functional composite (CFC). As a first validation step, we investigated its test-retest reliability and feasibility of use. Methods: We performed a test-retest study with 2-3 weeks between assessments, including patients with mild cognitive impairment (MCI) or mild AD dementia and cognitively healthy participants. We calculated intraclass correlation coefficients (ICCs) type absolute agreement for all CFC measures and compared baseline and retest scores using paired-samples t -tests...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780862/hospitalization-in-people-with-dementia-with-lewy-bodies-frequency-duration-and-cost-implications
#15
Christoph Mueller, Gayan Perera, Anto P Rajkumar, Manorama Bhattarai, Annabel Price, John T O'Brien, Clive Ballard, Robert Stewart, Dag Aarsland
Introduction: Increased hospitalization is a major component of dementia impact on individuals and cost, but has rarely been studied in dementia with Lewy bodies (DLB). Our aim was to describe the risk and duration of hospital admissions in patients with DLB, and compare these to those in Alzheimer's disease (AD) and the general population. Methods: A large database of mental health and dementia care in South London was used to assemble a cohort of patients diagnosed with DLB...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780861/the-relationship-between-recall-of-recently-versus-remotely-encoded-famous-faces-and-amyloidosis-in-clinically-normal-older-adults
#16
Irina Orlovsky, Willem Huijbers, Bernard J Hanseeuw, Elizabeth C Mormino, Trey Hedden, Rachel F Buckley, Molly LaPoint, Jennifer S Rabin, Dorene M Rentz, Keith A Johnson, Reisa A Sperling, Kathryn V Papp
Introduction: Alzheimer's disease (AD) patients exhibit temporally graded memory loss with remote memories remaining more intact than recent memories. It is unclear whether this temporal pattern is observable in clinically normal adults with amyloid pathology (i.e. preclinical AD). Methods: Participants were asked to recall the names of famous figures most prominent recently (famous after 1990) and remotely (famous from 1960-1980) and were provided with a phonemic cue to ensure that memory failure was not purely due to verbal retrieval weaknesses...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780860/microbleeds-are-associated-with-depressive-symptoms-in-alzheimer-s-disease
#17
Anna E Leeuwis, Niels D Prins, Astrid M Hooghiemstra, Marije R Benedictus, Philip Scheltens, Frederik Barkhof, Wiesje M van der Flier
Introduction: Co-occurrence of cerebrovascular disease and depression led to the "vascular depression hypothesis". White matter hyperintensities (WMHs) have been associated with depressive symptoms in population-based studies. We studied the association between small vessel disease and depressive symptoms in a memory clinic population. Methods: We included >2000 patients with subjective cognitive decline (SCD), mild cognitive impairment, and Alzheimer's disease (AD)...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780859/monoaminergic-impairment-in-down-syndrome-with-alzheimer-s-disease-compared-to-early-onset-alzheimer-s-disease
#18
Alain D Dekker, Yannick Vermeiren, Maria Carmona-Iragui, Bessy Benejam, Laura Videla, Ellen Gelpi, Tony Aerts, Debby Van Dam, Susana Fernández, Alberto Lleó, Sebastian Videla, Anne Sieben, Jean-Jacques Martin, Rafael Blesa, Juan Fortea, Peter P De Deyn
Introduction: People with Down syndrome (DS) are at high risk for Alzheimer's disease (AD). Defects in monoamine neurotransmitter systems are implicated in DS and AD but have not been comprehensively studied in DS. Methods: Noradrenaline, adrenaline, and their metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG); dopamine and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid; and serotonin and its metabolite 5-hydroxyindoleacetic acid were quantified in 15 brain regions of DS without AD (DS, n = 4), DS with AD (DS+AD, n = 17), early-onset AD (EOAD, n = 11) patients, and healthy non-DS controls (n = 10) in the general population...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29780858/can-visuospatial-measures-improve-the-diagnosis-of-alzheimer-s-disease
#19
REVIEW
Shirin Salimi, Muireann Irish, David Foxe, John R Hodges, Olivier Piguet, James R Burrell
Introduction: Overlapping and evolving symptoms lead to ambiguity in the diagnosis of dementia. Visuospatial function relies on parietal lobe function, which may be affected in the early stages of Alzheimer's disease (AD). This review evaluates visuospatial dysfunction in patients with AD, frontotemporal dementia, dementia with Lewy bodies, and vascular dementia to determine the diagnostic and prognostic potential of visuospatial tasks in AD. Methods: A systematic search of studies (1960-2016) investigating visuospatial dysfunction in dementia was conducted...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/29644327/regional-tract-specific-white-matter-hyperintensities-are-associated-with-patterns-to-aging-related-brain-atrophy-via-vascular-risk-factors-but-also-independently
#20
Mohamad Habes, Guray Erus, Jon B Toledo, Nick Bryan, Deborah Janowitz, Jimit Doshi, Henry Völzke, Ulf Schminke, Wolfgang Hoffmann, Hans J Grabe, David A Wolk, Christos Davatzikos
Introduction: We sought to investigate associations of regional white matter hyperintensities (WMHs) within white matter (WM) tracts with cardiovascular risk and brain aging-related atrophy throughout adulthood in the general population, leveraging state of the art pattern analysis methods. Methods: We analyzed a large sample (n = 2367) from the Study of Health in Pomerania, Germany (range 20-90 years). WMHs were automatically segmented on T1-weighted and fluid-attenuated inversion recovery magnetic resonance images, and WMH volumes were calculated in WM regions defined using the John Hopkins University WM tractography atlas...
2018: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
journal
journal
50108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"